How many insider trades does FilingIQ track for RNAZ?

FilingIQ tracks 14 Form 4 insider transactions for RNAZ (Transcode Therapeutics, Inc.), covering filings from May 27, 2022 onwards. 4 of those were filed in the last 90 days.

Are RNAZ insiders net buyers or net sellers?

Across the full Form 4 history for RNAZ, 10 transactions (71%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does RNAZ insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is RNAZ in?

Transcode Therapeutics, Inc. (RNAZ) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $7.87M.

RNAZ insider trading

Healthcare

Transcode Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

71% / 0%

Market cap

$7.87M

About Transcode Therapeutics, Inc.

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Company website: www.transcodetherapeutics.com

RNAZ insider activity at a glance

FilingIQ has scored 14 insider transactions for RNAZ since May 27, 2022. The most recent filing in our index is dated Aug 3, 2026.

Across the full history, 10 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on RNAZ insider trades is 67.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live RNAZ trades on FilingIQ Raw filings on SEC EDGAR

Latest RNAZ Form 4 filings

Dudley Robert Michael Chief Executive Officer

P Sep 28, 2023

Fitzgerald Thomas A Chief Financial Officer

P Sep 28, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 967

UNITED THERAPEUTICS Corp

APLS 271

Apellis Pharmaceuticals, Inc.

BLLN 208

BillionToOne, Inc.

KYMR 200

Kymera Therapeutics, Inc.

GH 195

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for RNAZ?: FilingIQ tracks 14 Form 4 insider transactions for RNAZ (Transcode Therapeutics, Inc.), covering filings from May 27, 2022 onwards. 4 of those were filed in the last 90 days.
Are RNAZ insiders net buyers or net sellers?: Across the full Form 4 history for RNAZ, 10 transactions (71%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does RNAZ insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is RNAZ in?: Transcode Therapeutics, Inc. (RNAZ) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $7.87M.

Methodology & sources

Every RNAZ insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.